

Gastrointestinal effects of prebiotics

J. H. Cummings* and G. T. Macfarlane

Department of Molecular and Cellular Pathology, University of Dundee,
Ninewells Hospital and Medical School, Dundee, DD1 9SY, UK

The defining effect of prebiotics is to stimulate selectively the growth of bifidobacteria and lactobacilli in the gut and, thereby, increase the body's natural resistance to invading pathogens. Prebiotic carbohydrates may also have additional, less specific, benefits because they are fermented in the large intestine. The prebiotic carbohydrates that have been evaluated in humans at the present time largely consist of fructans or galactans. There is consistent evidence from *in vitro* and *in vivo* studies that these are not digested by normal human enzymes, but are readily fermented by anaerobic bacteria in the large intestine. There are no reports of faecal recovery of measurable quantities of prebiotic carbohydrates. Through fermentation in the large intestine, prebiotic carbohydrates yield short-chain fatty acids, stimulate the growth of many bacterial species in addition to the selective effects on lactobacilli and bifidobacteria, they can also produce gas. Along with other fermented carbohydrates, prebiotics have mild laxative effects, although this has proved difficult to demonstrate in human studies because the magnitude of laxation is small. Potentially, the most important effect of prebiotic carbohydrates is to strengthen the body's resistance to invading pathogens and, thereby, prevent episodes of diarrhoea. At the present time, this effect has not been convincingly demonstrated in either adults or children, although there have been attempts to ameliorate the diarrhoea associated with antibiotics and travel, but without success. However, prebiotic carbohydrates clearly have significant and distinctive physiological effects in the human large intestine, and on the basis of this it is likely that they will ultimately be shown to be beneficial to health.

Prebiotics: Fermentation: Biofilm: Travellers' diarrhoea

Introduction

Prebiotics are food ingredients that stimulate selectively the growth and activity of bifidobacteria and lactobacilli in the gut and thereby benefit health. At the present time, all prebiotics described are short-chain carbohydrates with a degree of polymerisation of between two and about sixty, and are thought to be non-digestible by human, or animal digestive enzymes. However, the defining property of prebiotics is their effect on the microflora of the large bowel, so neither a specific chain length nor non-digestibility are essential to the definition, although such properties may be essential to their effect on health. Prebiotic proteins or lipids are unlikely to exist because of the nature of the metabolism of bifidobacteria and lactobacilli.

Prebiotics are an exciting new concept in human nutrition and digestive function for which, as is often the case with a new idea, many physiological and health claims have already been made. Table 1 lists these claims. Central to all claims is the effect on the microflora, which in turn

should lead to strengthening of colonisation resistance to pathogen invasion in the large bowel, and a reduction in diarrhoeal diseases. As yet, however, no clinical benefit in diarrhoea has been shown. Other important gastrointestinal effects include the general benefits of fermentation, which prebiotics share with non-starch polysaccharides and resistant starch, effects on mineral absorption, especially calcium, and possibly protection against tumour growth, as demonstrated in animal models. Any of these claims, if proven, will justify the present interest and research into prebiotics.

Digestion

Non-digestibility in the small bowel is assumed for prebiotics, but in fact, this has been established *in vivo* for few of these carbohydrates. Measuring digestion of any substance in the stomach and small bowel *in vivo* is difficult. One useful model is the ileostomy patient, with an alternative approach being the aspiration of residual digesta from the ileum using intubation. Table 2 shows that for inulin and

Note: For the definition of the terms inulin and oligofructose please refer to the introductory paper (p. S139) and its footnote.

* **Corresponding author:** Professor J. H. Cummings, fax +44 (0) 1382 633952, email j.h.cummings@dundee.ac.uk

Table 1. Claimed gastrointestinal effects of prebiotics

Through fermentation in the large bowel	
Production of short-chain fatty acids and lactate	
Gas, mainly CO ₂ and H ₂	
Increase in biomass	
Increased faecal energy and nitrogen	
Mild laxative properties	
On the microflora	
Selective increases in bifidobacteria and lactobacilli in planktonic and biofilm communities	
Reduction in clostridia	
Increase in colonisation resistance to pathogens	
Potential benefit in preventing pathogen invasion	
Small intestine	
Osmotic effect of low molecular weight prebiotics (DP3, 4) which occasionally causes diarrhoea	
Improved calcium, magnesium and iron absorption	
Interaction with mucus to change binding sites for bacteria, lectins etc.	
Mouth	
Protection against caries	
Other effects	
Bile acid metabolism—no consistent changes reported	
Variable effects on microbial enzymes with potential to affect carcinogenesis	
Stimulation of apoptosis	

oligofructose, both techniques indicate that at least 88 % of these ingested prebiotics reach the caecum.

Other evidence of non-digestibility is more circumstantial. Oligofructose (from sucrose, essentially GF₂ and GF₃) have been incubated *in vivo* with either human saliva or rat pancreatic homogenate and reported to be 'hardly digested' (Hidaka *et al.* 1986). No change in blood glucose or insulin was seen when 25 g of the same product was given to healthy subjects, nor when inulin extracted from Jerusalem artichokes (30 % GF₇ or greater) at doses of 5, 10 or 20 g, were taken either alone or with other carbohydrates (Hidaka *et al.* 1986; Rumessen *et al.* 1990). Nilsson *et al.* (1988) incubated various cereal inulins in fresh human gastric juice for 1 h and showed that at pH 1.05, 10–15 % was hydrolysed, but above pH 1.8 less than 1 % was degraded. When incubated with homogenised rat intestinal mucosa the rate of hydrolysis of inulin was less than 1 % that of sucrose. In the same study, inulin disappearance from the intubated rat small bowel *in vivo* was virtually nil. Earlier, McCance & Lawrence (1929) had shown inulin to be labile in gastric juice. A number of other studies have found that after intake of

prebiotics, breath hydrogen excretion increases. While this is evidence of their fermentability, it does not provide information on the true extent of their non-digestion (see later).

Fermentability

Having reached the caecum, prebiotic carbohydrates are highly likely to be fermented, since they are water soluble and relatively simple molecules. So completely are these carbohydrates fermented that feeding studies in humans of inulin and oligofructose have consistently failed to recover any of these materials in faeces (Table 3).

In vitro, prebiotic carbohydrates can be shown to support intestinal bacterial growth and produce various fermentation-derived end products. Two early studies (Hidaka *et al.* 1986; Mitsuoka *et al.* 1987) both showed that a range of bifidobacteria could utilise oligofructose (from sucrose) although other enteric bacteria were able to grow on a range of prebiotics, especially *Bacteroides* species. Utilisation of oligofructose by lactobacilli, *Escherichia coli* and *Clostridium perfringens* was poor. Using gas and short-chain fatty acid production as endpoints, Wang & Gibson (1993) showed that human faecal slurries fermented oligofructose, along with a wide range of other carbohydrates, but that inulin and oligofructose selectively stimulated the growth of bifidobacteria. In pure culture experiments, eight different bifidobacteria, including *B. bifidum*, grew well on oligofructose, as also did *E. coli* and *C. perfringens*, which was in direct contrast to the earlier results of Hidaka & Mitsuoka. However, these latter two organisms showed somewhat better growth rates on glucose, whereas of the bifidobacteria, only *B. longum* did. In competition experiments, Gibson & Wang (1994) showed that in pH controlled co-culture of *B. infantis*, *E. coli* and *C. perfringens* with oligofructose as sole carbohydrate substrate, the bifidobacteria grew well and exerted an inhibitory effect on the growth of *E. coli* and *C. perfringens*. These findings were subsequently confirmed *in vivo* in human feeding studies (Gibson *et al.* 1995).

The prebiotic properties of inulin and oligofructose are now well documented, but few groups have looked at the role of these carbohydrates in determining the composition of the mucosa-associated flora. When growing on surfaces, intestinal bacteria form biofilms (Macfarlane *et al.* 1999) and behave differently from those existing in a planktonic

Table 2. Digestibility of prebiotics in human upper intestine

Source	Model system	Intake (g)	Recovery (g)	% Recovered	Reference
Inulin	Ileostomy	7.07	6.1	86	Bach Knudsen & Hessov (1995)
Inulin		21.2	18.4	87	
Inulin	Ileostomy	17.0	15.0	88	Ellegard <i>et al.</i> (1997)
Oligofructose		15.5	13.8	89	
Oligofructose (from sucrose)	Aspiration from ileum	(20.1)	6.0	89	Molis <i>et al.</i> (1996)
Average recovery 88 %					

From Cummings *et al.* (2001b).

Table 3. Faecal recovery of inulin and oligofructose in humans

Literature	Source g/day	Recovery (g)
Kulz (1874)	Inulin 50–120 g	0
Persia (1905)	Inulin 'large doses'	0
Neubauer (1905)	Inulin 80 g	0
Lewis (1912)	Inulin 40–60 g	'no increase in faecal CHO'
Molis <i>et al.</i> (1996)	Oligofructose 20.1 g	0%
Alles <i>et al.</i> (1996)	Oligofructose 5 and 15 g	0

or free form. The biofilm communities of the gut epithelium may be more important in determining mucosal function, interacting with the gut associated immune system and in the catabolism of mucus. Using a novel design, (Horan & Cummings, 1999) glass fermentation chambers have been adapted to suspend several mucin-covered glass slides within a culture vessel. These are run at constant temperatures and pH and used to assess the effect of inulin and oligofructose on the planktonic and biofilm populations of bacteria. Faecal inocula from six healthy volunteers were used. After 12 h, the effect of the prebiotic mixture was to increase counts of bifido bacteria in the planktonic phase by 0.45 log₁₀ CFU/ml ($P=0.06$) and the biofilm count by 0.77 log₁₀ CFU/slide ($P<0.001$). Counts of clostridia fell and lactobacilli showed a small increase. As a follow-up to the *in vitro* work, Langlands *et al.* (2000) carried out a human feeding study to investigate this effect *in vivo*. Fifteen healthy subjects were selected from a colonoscopy waiting list and supplemented their usual diet with 15 g/day of an inulin + oligofructose mixture for 2 weeks before their colonoscopy. During this procedure, biopsy specimens of mucosa were removed for culture, and bacteria were identified according to their cellular fatty acid profiles (MIDI system). A group of age and sex matched healthy subjects attending for colonoscopy were used as controls. The effect on the mucosal flora was to increase significantly both bifidobacterial and lactobacilli counts on the epithelium. This was by one log CFU/g mucosa and 0.5 log CFU/g mucosa respectively, whilst counts of bacteroides, clostridia and enterobacteria were unchanged. This small feeding study has shown that the prebiotic effects of inulin and oligofructose may also be seen at the critical interface between the mucosa and surface-associated bacteria.

Whether the nature of the carbohydrate determines its fermentability is a question that has barely been addressed. Van Laere *et al.* (1997) produced a range of different short-chain carbohydrates with widely different sugar compositions and molecular sizes, and tested their breakdown by several strains of bifidobacteria, clostridia, bacteroides, lactobacilli, etc. Fermentability differed with oligosaccharide structure. The fructo-oligosaccharides were extensively fermented, except by the clostridia, while few species were able to breakdown arabinoxylan in the conditions of the experiment. Xylo-oligosaccharides were well fermented. Linear oligosaccharides were catabolised to a greater degree than those with branched structures while bifidobacteria utilised low degree of polymerisation (DP) carbohydrate first, and bacteroides those with a high DP. Metabolic collaboration amongst species was evident in

carbohydrate breakdown. Both the structure of the carbohydrate and the bacterial species present in the ecosystem are probably important factors in controlling fermentation of prebiotic carbohydrates.

The major products of prebiotic metabolism are short-chain fatty acids (SCFA), the gases H₂ and CO₂ and bacterial cell mass. Much has been written about SCFA production in the hindgut and of the differing metabolic significance of the individual acids (Cummings *et al.* 1995). Whilst prebiotics have been shown to be a source of SCFA both *in vitro* and *in vivo*, no particular distinguishing feature of the pattern of SCFA production has emerged as yet from *in vivo* studies in humans (Gibson *et al.* 1995; Luo *et al.* 1996; Alles *et al.* 1996; Kleesen *et al.* 1997).

The gases CO₂ and H₂ are inevitable products of fermentation but also provide the major clinical disincentive to consumption of prebiotics. Unwanted symptoms relating to gas production in the gut are widely reported in human prebiotic feeding studies. In Stone-Dorshow & Levitt's study (1987) twelve subjects took 15 g oligofructose (from sucrose) daily for 12 days. When compared with a group of five subjects taking sucrose, symptoms of abdominal pain, eructation, flatulence and bloating were all significantly more severe in the oligofructose group. There was no adaptation over the 12-day period but symptoms were all reported as no more than mild. Other studies of oligofructose at doses of 5 and 20 g/d have shown dose-related increases in breath H₂ and mild flatulence and borborygmi in general with isolated individuals experiencing somewhat more discomfort (Ito *et al.* 1990; Kawaguchi *et al.* 1993; Luo *et al.* 1996; Pedersen *et al.* 1997). Paradoxically eight healthy subjects taking 10 g/d transgalacto-oligosaccharides (TOS) reported no digestive symptoms and a decrease in breath H₂ excretion (Bouhnik *et al.* 1997). Inulin at a dose of 14 g/d led to highly significant increases in flatulence, rumbling, stomach and gut cramps, together with bloating in a group of 64 women in a double-blind crossover study over 4-week periods. Twelve per cent of the volunteers considered the flatulence severe and unacceptable. No adaptation in symptoms occurred over time (Pedersen *et al.* 1997).

An explanation of these various and idiosyncratic effects of prebiotics on symptomatology and H₂ metabolism is difficult to find. Wide individual variation is known to occur in response to fermentation of prebiotics, and the stoichiometry of fermentation differs from carbohydrates of varying chain length and monosaccharide composition (Christl *et al.* 1992). Using breath H₂ excretion, it has been shown

Table 4. Effects of prebiotics on bowel habit

Source	Dose (g/d)	n	Faecal weight g/d		Reference
			Control	Prebiotic	
Oligofructose	15	8	134	154*	Gibson <i>et al.</i> (1995)
Inulin	15	4	92	123	
Oligomate (52% GOS)	4.8	12	151	134	Ito <i>et al.</i> (1990)
	9.6	12		151	
	19.2	12		162	
TOS	10	8		No change	Bouhnik <i>et al.</i> (1997)
Oligofructose	5	24	272	279	Alles <i>et al.</i> (1996)
	15			264	

* $P < 0.05$ GOS=galacto-oligosaccharides; TOS=transgalacto-oligosaccharides.

that lactitol, isomaltose and polydextrose each increase breath H_2 by 112, 73 and 11% respectively, when given in equal doses to healthy subjects (Livesey *et al.* 1993). These findings were broadly reflected by *in vitro* fermentation studies and suggest that in general, molecules with longer chain length are fermented more slowly and with less net H_2 excretion. A similar result was obtained by Brighenti *et al.* (1995) when comparing lactulose, inulin and resistant starch (RS) in healthy subjects. Breath H_2 was only 4.7 ppm/h per g fed after RS compared with 19.1 for inulin and 26.6 for lactulose at a similar dose. In the studies of Christl (1992), who measured absolute H_2 excretion rates using a human calorimeter, total H_2 excretion for starch was only 40% of that from an equivalent dose of lactulose.

Prebiotics are clearly a major source of H_2 generation in the gut, and for some people the rapid formation of gas, and its volume, is a hindrance to consumption. Experiments to produce prebiotics of different chain lengths, degree of branching and DP might lead to less flatulent substrates – but this may alter their abilities to selectively influence the microflora.

Bowel habit

All carbohydrates that reach the large intestine have a laxative effect on bowel habit. Table 4 summarises those studies where bowel habit has been measured. The clearest demonstration of a laxative effect of prebiotics is in the controlled diet study of Gibson *et al.* (1995), which showed that 15 g of oligofructose increased stool output significantly from 136 to 154 g/d ($n = 8$) and in a smaller

Table 5. Faecal nitrogen (g/d \pm SEM) and energy excretion (kJ/day \pm SEM) from subjects fed 15 g inulin or oligofructose daily compared to a sucrose control period

n = 8	Sucrose	Oligofructose	Sucrose
Nitrogen	1.51 (0.12)	1.83 (0.17)*	1.55 (0.19)
Energy	597 (56)	696 (78)	640 (83)
n = 4	Sucrose	Inulin	
Nitrogen	1.31 (0.16)	1.56 (0.14)*	
Energy	466 (42)	565 (64)	

* Significantly different from sucrose. From Gibson *et al.* (1995).

group of subjects 15 g of inulin was also laxative; 92 g/d control, 123 g/d inulin ($n = 4$). Three other human experiments have not shown an increase in stool output (Table 4) but in none was diet controlled, which would tend to mask a small effect. In the study of Alles *et al.* (1996), subjects started with unusually high faecal weights on the control diet, 272 ± 26 g/d. In that of Bouhnik *et al.* (1997) volunteers were given 10 g transgalacto-oligosaccharides daily for 21 days without effect on bowel habits. Ito *et al.* (1990) who fed 4.8–19.2 g/d oligomate (52% galacto-oligosaccharides) to twelve healthy subjects were also unable to demonstrate a change in bowel habit, despite showing bifidogenicity and the subjects reporting an increase in abdominal symptoms. In studies reporting only qualitative data, either oligofructose or inulin 'improved' constipation in small groups of hospitalised subjects (Sanno, 1987; Hidaka & Hirayama, 1991; Kleesen *et al.* 1997).

Inulin and oligofructose are probably laxative, but because the effect is small it is difficult to detect except in carefully controlled studies. The increase in faecal output is likely to be due to an increase in biomass. Alongside the increase in dry matter excretion is a significant increase in nitrogen (Table 5). In the study of Gibson *et al.* (1995), the additional excretion of 0.32 g/d nitrogen when oligofructose was added to the diet is equivalent to 5 g of bacterial solids which, at the moisture content of stool, is equivalent to 20–25 g of wet stool. This was exactly the change in stool output seen in the study.

Travellers' diarrhoea

Demonstrating a direct clinical or health benefit of prebiotics is proving difficult. Small changes in lipid metabolism, calcium absorption or immune function may not give rise to evident improvements in health for many years. However, resistance to pathogen invasion through increased colonisation resistance of the gut flora, brought about by stimulation of bifidobacteria and lactobacilli, should in principle be easier to show *in vivo*. Oligofructose has been reported to protect hamsters against *C. difficile* infection (Wolf *et al.* 1997) but studies in humans have so far been unsuccessful (Lewis & Cohen, 2000). However, most *C. difficile* infection is associated with antibiotic use and it would be surprising if prebiotic carbohydrates

were able to protect the resident gut bacterial from the effect of antibiotics.

An alternative clinical situation in which to test prebiotics is that of travellers' diarrhoea. Travellers' diarrhoea remains a common problem for those journeying overseas for either business or holidays. It is particularly frequent in visitors to Central America, the Far East, India and parts of Africa. Current estimates are that 60 million travellers from the West visit high-risk areas annually, and of these, 30–50% have episodes of diarrhoea. The infecting organisms are very much the same as those that cause acute diarrhoea in both developed and developing countries, e.g. salmonella, shigella, campylobacter, enterotoxigenic and other *E. coli*, protozoa such as *Giardia lamblia* and *Entamoeba histolytica*, and viruses, especially rotavirus. Part of the defence against invading organisms is the indigenous flora of the hindgut such as bifidobacteria and lactobacilli, both of which colonise adhesion sites and secrete bacteriostatic peptides, which are part of the process whereby invading pathogens are repelled. A preventive and therapeutic strategy that has been tried in the past is to supplement those at risk of diarrhoea, or suffering an acute attack, with oral doses of probiotic organisms, such as lactobacilli. These bacteria have been shown to survive gastric acid and adhere to small intestinal mucosa. Through this mechanism they are thought to prevent the adhesion of pathogenic bacteria and thus protect against diarrhoea or reduce the severity of attacks. However, in published studies where probiotic bacteria have been tried in travellers' diarrhoea, the degree of protection has been relatively small at around 10% (Lewis & Freedman, 1998; Gismondo *et al.* 1999; de Roos & Katan, 2000). Nevertheless, altering the environment in the hindgut towards a flora in which bifidobacteria are the predominant species using oral fructo-oligosaccharides, may provide a simple way of reducing morbidity in travellers to endemic regions of diarrhoea.

A study was therefore undertaken (Cummings *et al.* 2001a) in 244 healthy subjects, travelling to high and medium risk destinations for travellers' diarrhoea. The protocol was a randomised, double-blind, placebo-controlled study, comprising a preliminary week for recording bowel habit by diary, a 2-week pre-holiday period with the diary and consumption of 10 g of oligofructose or placebo daily, followed by a 2-week holiday with continuation of treatment and diary. A post-study

questionnaire (PSQ) was completed by all subjects on their return to the UK. Consumption of oligofructose led to a small, 6% ($P < 0.02$) increase in stool frequency in the pre-holiday period, while some subjects reported more flatulence. There were non-significant decreases in episodes of diarrhoea (Table 6) with 20% on placebo and 11% on oligofructose recording episodes in the PSQ ($P = 0.08$) and 46% placebo, 38% FOS in the diary ($P > 0.1$). No change in bowel frequency, consistency or stool size was recorded (Table 6).

In this study, oligofructose failed to prevent diarrhoea, but did give subjects an increased sense of well-being while on holiday. However, 42% of subjects experienced diarrhoea whilst on holiday, which is a striking reminder of the prevalence of the problem in travellers.

A likely reason for the failure of oligofructose to prevent travellers' diarrhoea may lie in its mechanism of action and in the aetiology of diarrhoea in travellers. Oligofructose primarily affects the large intestinal microflora and may well improve colonisation resistance. However, there are multiple causes of diarrhoea in travellers, other than those that target the large intestine. Many pathogens affect the small bowel, for example, aeromonas, enteropathogenic and enterotoxigenic *E. coli*, campylobacter, giardia, salmonella and vibrios. In order to prevent the effect of these and similar organisms a preventive strategy aimed at the small intestine would be required. Furthermore, in all reported studies where the aetiological agent of diarrhoea has been sought in travellers, in at least 20% no organism has been identified. Whilst this failure to identify an incriminating pathogen has often been ascribed to inadequacy of microbiological methods, sampling problems etc, it is equally likely that subjects experience episodes of diarrhoea for reasons other than simple infection. Many people travelling abroad eat unusual foods to which they may never have been exposed, and which may cause food intolerance and diarrhoea. Equally, people on holiday may take far more alcohol than usual and again this is known to upset bowel habit. Overall, therefore, the multiple causes of diarrhoea in travellers make it unlikely that a single preventive strategy will be effective.

Conclusion

Prebiotics are an exciting and challenging new concept in

Table 6. Effect of oligofructose on diarrhoea in subjects travelling to high and medium risk areas

	Placebo	Oligofructose	<i>P</i>
Number of stools (14-day holiday period)	20.3 (6.1)	21.3 (8.2)	0.3
Frequency (%) of symptoms from post study questionnaire			
• bloating	7.8	11.2	0.5
• flatulence	18.8	34.5	0.03
• diarrhoea	19.5	11.2	0.08
• constipation	10.2	10.3	0.99
• less irritable bowel symptoms	3.9	7.8	0.3
• feeling well	4.7	12.9	0.04

From Cummings *et al.* (2001a).

nutrition and digestive function. They are normal constituents of the diet, selectively stimulate the growth of beneficial bacteria in the large bowel, are safe and potentially of benefit to health. Any prudent diet should contain quantities of prebiotics. While the mechanism of their effect in gut bacteria is slowly being discovered, their effects on health are much more difficult to demonstrate. Nevertheless, this is an important new area for food and nutrition science.

References

- Alles MS, Hautvast JGAJ, Nagengast FM, Hartemink R, Van Laere KMJ & Jansen JBM (1996) Fate of fructo-oligosaccharides in the human intestine. *British Journal of Nutrition* **76**, 211–221.
- Bach Knudsen KE & Hessov I (1995) Recovery of inulin from Jerusalem artichoke (*Helianthus tuberosus* L) in the small intestine of man. *British Journal of Nutrition* **74**, 101–103.
- Bouhnik Y, Flourie B & D'Agay-Abensour L, *et al.* (1997) Administration of transgalacto-oligosaccharides increases fecal bifidobacteria and modifies colonic fermentation metabolism in healthy humans. *Journal of Nutrition* **127**, 444–448.
- Brighenti F, Casiraghi MC, Pellingrini N, Riso P, Simonetti P & Testolin G (1995) Comparison of lactulose and inulin as reference standard for the study of resistant starch fermentation using hydrogen breath test. *Italian Journal of Gastroenterology* **27**, 122–128.
- Christl SU, Murgatroyd PR, Gibson GR & Cummings JH (1992) Production, metabolism and excretion of hydrogen in the large intestine. *Gastroenterology* **102**, 1269–1277.
- Cummings JH, Christie S & Cole TJ (2001a) A study of fructo oligosaccharides (FOS) in the prevention of travellers' diarrhoea. *Alimentary Pharmacology and Therapeutics* **15**, 1139–1145.
- Cummings JH, Macfarlane GT & Englyst HN (2001b) Prebiotic digestion and fermentation. *American Journal of Clinical Nutrition* **73**, 415S–420S.
- Cummings JH, Rombeau JL & Sakata T (1995) *Physiological and Clinical Aspects of Short Chain Fatty Acids*. Cambridge: Cambridge University Press.
- de Roos NM & Katan MB (2000) Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. *American Journal of Clinical Nutrition* **71**, 405–411.
- Ellegard L, Andersson H & Bosaeus I (1997) Inulin and oligo-fructose do not influence the absorption of cholesterol, or the excretion of cholesterol, Ca, Mg, Zn, Fe, or bile acids but increases energy excretion in ileostomy subjects. *European Journal of Clinical Nutrition* **51**, 1–5.
- Gibson GR, Beatty ER, Wang X & Cummings JH (1995) Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin. *Gastroenterology* **108**, 975–982.
- Gibson GR & Wang X (1994) Regulatory effects of bifidobacteria on the growth of other colonic bacteria. *Journal of Applied Bacteriology* **77**, 412–420.
- Gismondo MR, Drago L & Lombardi A (1999) Review of probiotics available to modify gastrointestinal flora. *International Journal of Antimicrobial Agents* **12**, 287–292.
- Hidaka H, Eida T, Takizawa T, Tokunaga T & Tashiro Y (1986) Effects of fructooligosaccharides on intestinal flora and human health. *Bifidobacteria Microflora* **5**, 37–50.
- Hidaka H & Hirayama M (1991) Useful characteristics and commercial applications of fructooligosaccharides. *Biochemical Society Transactions* **19**, 561–565.
- Horan SJ & Cummings JH (1999) Inulin and oligofructose modify surface associated human colonic bacteria *in vitro*. *Gut* **45**, A37.
- Ito M, Deguchi Y & Miyamori A, *et al.* (1990) Effects of administration of galactooligosaccharides on the human faecal microflora, stool weight and abdominal sensation. *Microbial Ecology Health Disease* **3**, 285–292.
- Kawaguchi M, Tashiro Y, Adachi T & Tamura Z (1993) Changes on intestinal condition, fecal microflora and composition of rectal gas after administration of fructooligosaccharide and lactulose at different doses. *Bifidobacteria Microflora* **13**, 57–68.
- Kleessen B, Sykura B, Zunft H-J & Blaut M (1997) Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. *American Journal of Clinical Nutrition* **65**, 1397–1402.
- Külz (1874) Beiträge zur Pathologie und Therapie des Diabetes Mellitus. *Marburg Jahrbuch Tierchemie* **IV**, 448.
- Langlands SJ, Hopkins MJ & Cummings JH (2000) Inulin and FOS feeding modify colonic mucosal bacteria *in vivo*. *Gastroenterology* **118**, A772, Suppl 2 part of 1.
- Lewis HB (1912) The value of inulin as a foodstuff. *Journal of the American Medical Association* **58**, 1176–1177.
- Lewis S & Freedman AR (1998) Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. *Alimentary Pharmacology and Therapeutics* **12**, 807–822.
- Lewis SJ & Cohen S (2000) Prevention of antibiotic associated diarrhoea with oligofructose. *Gut* **465**, A70.
- Livesey G, Johnson IT & Gee JM, *et al.* (1993) Determination of sugar alcohol and polydextrose absorption in humans by the breath hydrogen (H₂) technique: the stoichiometry of hydrogen production and the interaction between carbohydrates assessed *in vivo* and *in vitro*. *European Journal of Clinical Nutrition* **47**, 419–430.
- Luo J, Rizkalla SW & Alamowitch C, *et al.* (1996) Chronic consumption of short-chain fructooligosaccharides by healthy subjects decreased basal hepatic glucose production but had no effect on insulin-stimulated glucose metabolism. *American Journal of Clinical Nutrition* **63**, 939–945.
- Macfarlane S, Cummings JH & Macfarlane GT (1999) Bacterial colonisation of surfaces in the large intestine. In *Colonic Microbiota, Nutrition and Health*, pp. 71–87 [GR Gibson and MB Roberfroid, editors]. Netherlands: Kluwer Academic Publishers.
- McCance RA & Lawrence RD (1929) *The Carbohydrate Content of Foods*. HMSO: London.
- Mitsuoka T, Hidaka H & Eida T (1987) Effect of fructooligosaccharides on intestinal microflora. *Nahrung* **31**, 5–6.
- Molis C, Flourie B & Ouarne F, *et al.* (1996) Digestion, excretion, and energy value of fructooligosaccharides in healthy humans. *American Journal of Clinical Nutrition* **64**, 324–328.
- Neubauer (1905), *München Medizinische Wochenschrift* p. 1525.
- Nilsson U, Oste R, Jagerstad M & Birkhed D (1988) Cereal fructans: *in vitro* and *in vivo* studies on availability in rats and humans. *Journal of Nutrition* **118**, 1325–1330.
- Pedersen A, Sandstrom B & Van Amelsvoort JMM (1997) The effect of ingestion of inulin on blood lipids and gastrointestinal symptoms in healthy females. *British Journal of Nutrition* **78**, 215–222.
- Persia (1905) Nuova Revista Clinica Therapeutica. *Jahresbuch Tierchemie* **XXV**, 822.
- Rumessen JJ, Bode S, Hamberg O & Gudmand-Hoyer E (1990) Fructans of Jerusalem artichokes: intestinal transport, absorption, fermentation and influence on blood glucose, insulin and

- C-peptide responses in healthy subjects. *American Journal of Clinical Nutrition* **52**, 675–681.
- Sanno T (1987) Effects of Neosugar on constipation, intestinal microflora, and gall bladder contraction in diabetics. Proceedings of the Third Neosugar Research Conference, Tokyo, 1986. Tokyo: Meiji-Seika Publications, 109–117.
- Stone-Dorshow T & Levitt MD (1987) Gaseous response to ingestion of a poorly absorbed fructooligosaccharide sweetener. *American Journal of Clinical Nutrition* **46**, 61–65.
- Van Laere KMJ, Bosveld M, Schols HA, Beldman G & Voragen AGJ (1997) Fermentative degradation of plant cell wall derived oligosaccharides by intestinal bacteria. In Non-digestible Oligosaccharides: Healthy Food for the Colon? [R Hartemink, editor] Proceedings of the International Symposium, Wageningen Graduate School VLAG. Wageningen, Netherlands: Wageningen Graduate School VLAG, 37–46.
- Wang X & Gibson GR (1993) Effects of the *in vitro* fermentation of oligofructose and inulin by bacteria growing in the human large intestine. *Journal of Applied Bacteriology* **75**, 373–380.
- Wolf BW, Meulbroek JA, Jarvis KP, Wheeler KP & Garleb KA (1997) Dietary supplementation with fructooligosaccharides increase survival time in a hamster model of *Clostridium difficile* – colitis. *Bioscience Microflora* **16**, 59–64.